Evaluation of secondary stability in Healthy and Diabeticindividuals using conventional SLA implants andTrabecular Tantalum implants. A Randomized controlledtrial.

Geetha Arul Mohan0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•Inclusion criteria for diabetic individuals:
•1.diabetic patients with HbA1C: 6.1-8 [Group III and group IV]
•2.Patients who are between 18-60 years of age
•3.All sites had to be healed sites, that is at least 6 months of post extraction healing was required
•4.Mandibular edentulous sites
•Inclusion criteria for healthy individuals:
•1.Non diabetic patients with HbA1C- less than 6.1 [Group I and group II]
•2.Patients who are between 18-60 years of age
•3.All sites had to be healed sites, that is at least 6 months of post extraction healing was required
•4.Mandibular edentulous sites

•Exclusion criteria for diabetic individuals:
•1.HbA1C levels exceeding 8 are excluded
•2.History of oral /intravenous bisphosphonate use for >3 years
•4.Pregnancy or lactation
•5.Known allergy to any material or medication used in the study
•6.Any Previous History of head and neck radiation therapy
•7.Chemotherapy in the last 12 months
•8.Severe psychologic problems
•9.Patient not willing to sign the consent approved by the Human Studies Committee
•10.Debilitating systemic diseases or conditions that have a clinically significant effect on wound healing
•Exclusion criteria for healthy individuals:
•1.HbA1C levels exceeding 6.1 are excluded[Group I and group II]
•2.History of oral /intravenous bisphosphonate use for >3 years
•4.Pregnancy or lactation
•5.Known allergy to any material or medication used in the study
•6.Any Previous History of head and neck radiation therapy
•7.Chemotherapy in the last 12 months
•8.Severe psychologic problems
•9.Patient not willing to sign the consent approved by the Human Studies Committee
•10.Debilitating systemic diseases or conditions that have a clinically significant effect on wound

发起方

Geetha Arul Mohan